|  |  |  |  |
| --- | --- | --- | --- |
|  | TYA survivors on  treatment (n=67) | TYA survivors off  treatment (n=135) | p-value |
| Age at diagnosis, mean (SD) | 17.80 (3.25) | 16.27 (4.31) | 0.015 |
| Health problem present, % (n) | 67.16 (45) | 60.74 (82) | 0.791 |
| *Osteoporosis* | 1.49 (1) | 4.44 (6) |  |
| *Diabetes* | 7.46 (5) | 1.48 (2) |  |
| *Asthma* | 10.45 (7) | 10.37 (14) |  |
| *Irregular heart rhythm* | 7.46 (5) | 5.19 (7) |  |
| *Extreme fatigue* | 35.82 (24) | 29.63 (40) |  |
| *Mental health problems* | 16.42 (11) | 20.00 (27) |  |
| *Lung disease* | 0 (0) | 0.74 (1) |  |
| *Arthritis* | 1.49 (1) | 2.96 (4) |  |
| *Any other heart trouble* | 1.49 (1) | 2.22 (3) |  |
| *Another cancer* | 2.98 (2) | 1.48 (1) |  |
| *Sensory impairment* | 1.49 (1) | 3.70 (5) |  |
| *Other* | 19.40 (13) | 19.25 (26) |  |
| Treatment type, % (n) | | | 0.827 |
| *Chemotherapy or radiotherapy* | 95.52 (64) | 94.81 (128) |  |
| *No chemotherapy or radiotherapy* | 4.48 (3) | 5.19 (7) |  |
| Cancer type, % (n) | | | 0.015 |
| *Leukemia* | 32.84 (22) | 24.44 (33) |  |
| *Lymphoma* | 26.87 (18) | 35.56 (48) |  |
| *Carcinoma* | 0 (0) | 4.44 (6) |  |
| *Germ cell tumor* | 0 (0) | 3.70 (5) |  |
| *CNS tumor* | 0 (0) | 2.22 (3) |  |
| *Melanoma* | 1.49 (1) | 0.74 (1) |  |
| *Bone tumor* | 4.48 (3) | 9.63 (13) |  |
| *Soft tissue tumor* | 14.92 (10) | 3.70 (5) |  |
| *Other* | 17.91 (12) | 14.07 (19) |  |
| *Missing* | 1.49 (1) | 1.48 (2) |  |
| Cancer stage at diagnosis, % (n) | | | 0.222 |
| *0* | 0 (0) | 0.74 (1) |  |
| *I* | 11.94 (8) | 6.67 (9) |  |
| *II* | 11.94 (8) | 20.00 (27) |  |
| *III* | 11.94 (8) | 16.30 (22) |  |
| *IV* | 13.4 (9) | 11.85 (16) |  |
| *Don’t know* | 47.76 (32) | 40.74 (55) |  |
| *Don’t want to answer* | 0 (0) | 0.74 (1) |  |
| *Missing* | 2.99 (2) | 2.96 (4) |  |
| Time since active treatment, % (n) |  |  |  |
| *Less than 3 months* |  | 14.08 (19) |  |
| *Between 4 and 11 months* |  | 20.00 (27) |  |
| *Between 1 and 5 years* |  | 45.19 (61) |  |
| *More than 5 years* |  | 3.70 (5) |  |
| *On active surveillance* |  | 12.59 (17) |  |
| *Missing* |  | 4.44 (6) |  |

TABLE 2 Health characteristics of the study population